Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension

Angiotensin II (Ang II) acts at the cellular level on two receptor subtypes : the AT1 receptor which can be blocked by losartan and its analogues (the 'sartan family'), and the AT2 receptor that does not react with the above a ntagonists but which can be blocked by different compounds, such as PD12331 9. AT1 receptor blockade has proven to be a highly effective means of inter ference with the renin-angiotensin system (RAS) and hence of reducing high blood pressure. As a result of the terminal blockade of the RAS cascade, ci rculating Ang II levels tend to rise two- to threefold. The free access of such enhanced levels to uninhibited AT2 receptors may be clinically relevan t, as argued in the present review. The most extensive experimental and cli nical experience with ATI receptor blockade so far has been obtained with t he pioneer drug losartan, although major contributions have also been made on candesartan cilexetil, irbesartan and valsartan, All of these four drugs have been instrumental in substantial clinical trials, serving as sources of information in the clinically oriented part of this review. AT1 receptor blocking drugs generally provide a relatively gradual decrease in blood pr essure, which is comparable to that obtained with conventional anti-hyperte nsive drugs. Clinical trials reveal an astounding lack of drug-related adve rse effects, scoring even better than placebo in terms of frequencies and s ometimes patterns. The trough/peak ratio on single dosages seems to have be en mastered, particularly with the second generation of AT1 receptor blocke rs, as is evident from 24 h ambulatory blood pressure monitoring. Combinati on with low-dose thiazide regimens is well established. Intermediate endpoi nts (micro-albuminuria and left ventricular hypertrophy) appear to be contr ollable. Morbid cardiovascular sequelae are currently under study in compar ison with beta- and calcium channel blockade. I Hypertens 1999, 17:873-881 (C) Lippincott Williams & Wilkins.